ExodusPoint Capital Management’s Crinetics Pharmaceuticals CRNX Stock Holding History

ExodusPoint Capital Management’s Portfolio CRNX Stock Details CRNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-116,322	Closed	-$5.21M	–	1697
2024 Q2	$5.21M	Buy	116,322 +87,203	+299%	+$4.03M	0.04%	391
2024 Q1	$1.36M	Sell	29,119 -98,563	-77%	-$3.86M	0.01%	844
2023 Q4	$4.54M	Buy	127,682 +98,743	+341%	+$3.03M	0.03%	364
2023 Q3	$861K	Sell	28,939 -163,035	-85%	-$3.36M	0.01%	1014
2023 Q2	$3.46M	Buy	191,974 +44,858	+30%	+$895K	0.03%	585
2023 Q1	$2.36M	Buy	+147,116	New	+$2.72M	0.02%	811

Other funds holding CRNX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

ExodusPoint Capital Management's CRNX Position: Q3 2024 in Review

ExodusPoint Capital Management sold out of Crinetics Pharmaceuticals (CRNX) in Q3 2024, closing a stake of 116,322 shares — an estimated $5.21M sold.

ExodusPoint Capital Management first reported a position in CRNX in Q1 2023 and held it in 6 quarters. The position peaked at $5.21M in Q2 2024. 235 funds tracked by Wall St. Rank hold CRNX as of Q3 2024.

ExodusPoint Capital Management reported no remaining Crinetics Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
ExodusPoint Capital Management sold 116,322 Crinetics Pharmaceuticals shares in Q3 2024, an estimated $5.21M.
ExodusPoint Capital Management first reported a position in Crinetics Pharmaceuticals in Q1 2023 and held it in 6 quarters.
ExodusPoint Capital Management's Crinetics Pharmaceuticals position peaked at $5.21M in Q2 2024.
235 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q3 2024.

Based on ExodusPoint Capital Management's 13F filing for Q3 2024, filed 12 Nov 2024.